Literature DB >> 16762540

Conventional diagnostics in multiple myeloma.

Jesús F San Miguel1, Norma C Gutiérrez, Gema Mateo, Alberto Orfao.   

Abstract

This paper reviews the most relevant laboratory techniques currently used for the evaluation of patients with multiple myeloma (MM) and other monoclonal gammopathies. Although the bone marrow morphological examination and electrophoretic analysis of the monoclonal paraprotein still remain the 'gold standard' techniques for fast, accurate and cost-effective diagnosis, other assays such as immunophenotyping, DNA cell content and cell cycle analysis measured by flow cytometry may contribute to a better assessment of myeloma patients. Here, we will discuss not only the contribution of each technique to differential diagnosis of monoclonal gammopathies, but also the value of each parameter as prognostic factor and for monitoring treatment efficacy. In addition, possible technical pitfalls inherent to each technique will be analysed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16762540     DOI: 10.1016/j.ejca.2005.11.039

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  21 in total

1.  Detection of serum tumor markers in multiple myeloma using the CLINPROT system.

Authors:  Aili He; Ju Bai; Chen Huang; Juan Yang; Wanggang Zhang; Jianli Wang; Yun Yang; Pengyu Zhang; Fuling Zhou
Journal:  Int J Hematol       Date:  2012-04-27       Impact factor: 2.490

2.  CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype.

Authors:  Teresa Paíno; Enrique M Ocio; Bruno Paiva; Laura San-Segundo; Mercedes Garayoa; Norma C Gutiérrez; M Eugenia Sarasquete; Atanasio Pandiella; Alberto Orfao; Jesús F San Miguel
Journal:  Haematologica       Date:  2012-02-07       Impact factor: 9.941

3.  Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation.

Authors:  Bruno Paiva; Maria-Belén Vidriales; Jorge Cerveró; Gema Mateo; Jose J Pérez; Maria A Montalbán; Anna Sureda; Laura Montejano; Norma C Gutiérrez; Alfonso García de Coca; Natalia de Las Heras; Maria V Mateos; Maria C López-Berges; Raimundo García-Boyero; Josefina Galende; Jose Hernández; Luis Palomera; Dolores Carrera; Rafael Martínez; Javier de la Rubia; Alejandro Martín; Joan Bladé; Juan J Lahuerta; Alberto Orfao; Jesús F San Miguel
Journal:  Blood       Date:  2008-07-31       Impact factor: 22.113

4.  Unusual manifestation of a multiple myeloma in the hyoid bone.

Authors:  V Sychra; D Eßer; H Kosmehl; M Herold
Journal:  Dentomaxillofac Radiol       Date:  2012-01-12       Impact factor: 2.419

5.  A CD138-independent strategy to detect minimal residual disease and circulating tumour cells in multiple myeloma.

Authors:  Barbara Muz; Pilar de la Puente; Feda Azab; Micah John Luderer; Justin King; Ravi Vij; Abdel Kareem Azab
Journal:  Br J Haematol       Date:  2016-01-05       Impact factor: 6.998

6.  Plasma cell enrichment enhances detection of high-risk cytogenomic abnormalities by fluorescence in situ hybridization and improves risk stratification of patients with plasma cell neoplasms.

Authors:  Gary Lu; Ramya Muddasani; Robert Z Orlowski; Lynne V Abruzzo; Muzaffar H Qazilbash; M James You; Yaping Wang; Ming Zhao; Su Chen; Isabella Claudia Glitza; L Jeffrey Medeiros
Journal:  Arch Pathol Lab Med       Date:  2013-05       Impact factor: 5.534

7.  Three-dimensional Nuclear Telomere Organization in Multiple Myeloma.

Authors:  Ludger Klewes; Rhea Vallente; Eric Dupas; Carolin Brand; Dietrich Grün; Amanda Guffei; Chirawadee Sathitruangsak; Julius A Awe; Alexandra Kuzyk; Daniel Lichtensztejn; Pille Tammur; Tiiu Ilus; Anu Tamm; Mari Punab; Morel Rubinger; Adebayo Olujohungbe; Sabine Mai
Journal:  Transl Oncol       Date:  2013-12-01       Impact factor: 4.243

8.  Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients.

Authors:  Bruno Paiva; Maria-Belén Vidriales; Jose J Pérez; Gema Mateo; Maria Angeles Montalbán; Maria Victoria Mateos; Joan Bladé; Juan José Lahuerta; Alberto Orfao; Jesús F San Miguel
Journal:  Haematologica       Date:  2009-11       Impact factor: 9.941

9.  Current trends in the diagnosis, therapy and monitoring of the monoclonal gammopathies.

Authors:  Peter Mollee
Journal:  Clin Biochem Rev       Date:  2009-08

10.  Cytogenetic profiles in multiple myeloma and monoclonal gammopathy of undetermined significance: a study in highly purified aberrant plasma cells.

Authors:  Martin Schmidt-Hieber; María Laura Gutiérrez; Martin Pérez-Andrés; Bruno Paiva; Ana Rasillo; Maria Dolores Tabernero; José Maria Sayagués; Antonio Lopez; Paloma Bárcena; María Luz Sanchez; Norma C Gutiérrez; Jesus F San Miguel; Alberto Orfao
Journal:  Haematologica       Date:  2012-08-28       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.